IDH1 and IDH2 mutations in gliomas.

By F. Ducray, Y. Marie, M. Sanson. New England Journal of Medicine, 2009

2,870 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/1d38b52ee39a6ab617455e4816d1a8914791b97c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

The Definition of Primary and Secondary Glioblastoma (2012, background): “at other organ sites, including bladder, breast, stomach, colorectum, lung, liver, ovary, and prostate (12, 15).”
Mitochondria: In Sickness and in Health (2012, background): “Defects in succinate dehydrogenase, fumarate hydratase, and isocitrate dehydrogenase (IDH1) cause inherited paragangliomas, pheochromocytomas, myomas, and gliomas, respectively (Baysal et al., 2000; Tomlinson et al., 2002; Yan et al., 2009).”
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases (2011, background): “The NADP-dependent isocitrate dehydrogenase genes IDH1 and IDH2 are mutated in >75% of low grade gliomas and secondary glioblastoma multiforme (GBM) and 20% of acute myeloid leukemia (AML) (Mardis et al., 2009; Parsons et al., 2008; Yan et al., 2009).”
Glutaminolysis: A Hallmark of Cancer Metabolism. (2017, background): “Other cancers, such as acute myeloid leukemia and chondrosarcomas, bear both IDH1 R132 and IDH2 arginine 140 and arginine 172 mutations (115, 116).”
Glioblastoma: pathology, molecular mechanisms and markers (2015, background): “In addition to providing insights about the origin of gliomas, the mutational status of IDH1/2 serves as a prognostic marker in patients with WHO grade II and III gliomas [58, 123, 141, 181] and GBMs [172].”
Glioma Subclassifications and Their Clinical Significance (2017, background): “In gliomas, they were initially identified in a high percentage of LGGs and secondary GBMs and a lower percentage of primary GBMs [12].”
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010, background): “Cytosolic isocitrate dehydrogenase 1 (IDH1) mutations were initially detected in a fraction of glioblastomas [14] followed by the observation that they are present in the majority of diffuse astrocytomas, oligodendrogliomas and mixed oligoastrocytomas of WHO grades II and III [1, 7, 9, 22, 26].”